Cartalax (AED Tripeptide) Research Guide: Cartilage Biology & Bioregulator Peptide Research

Overview

Cartalax is the trade designation for the synthetic tripeptide Ala-Glu-Asp (AED), a member of the peptide bioregulator class originally developed through Russian gerontological and molecular biology research programs. Structurally, Cartalax consists of three amino acid residues — alanine, glutamic acid, and aspartic acid — joined in a linear sequence, with a molecular formula of approximately C₁₂H₁₉N₃O₈ and a molecular weight of approximately 333.3 g/mol.

Cartalax belongs to a broader family of short peptide bioregulators, sometimes referred to as “Khavinson peptides” after the research group most closely associated with their development, which also includes related short peptides studied for tissue-specific regulatory activity. Within this class, Cartalax (AED) has been studied specifically in relation to cartilage and connective tissue biology. This guide focuses exclusively on published cartilage- and chondrocyte-related research findings rather than usage protocols; researchers seeking handling or protocol information should consult the separate protocol resource maintained at /cartalax-20mg-protocol/. Available for research at Iron Peak Peptides: Cartalax.

The bioregulator peptide concept, as developed in this research tradition, is built on the premise that very short peptides — typically two to seven amino acid residues in length — can exert tissue-selective regulatory effects that are distinct from the receptor-mediated signaling mechanisms associated with larger signaling peptides and growth factors. Cartalax is one of a series of such short peptides studied for organ- or tissue-specific activity, with cartilage and connective tissue identified as its primary area of research interest, distinguishing it from other bioregulator peptides in the same structural family that have instead been studied in relation to skin, vascular, or neural tissue.

Mechanism of Action

Short peptide bioregulators such as Cartalax are proposed to act, at least in part, through direct interaction with nuclear chromatin. Published biophysical and molecular modeling research on this peptide class describes short peptides binding to specific nucleotide sequences within DNA promoter regions and interacting with histone proteins, including H1, H4, and related histone subtypes, through hydrogen bonding and electrostatic interactions. This DNA- and histone-binding activity has been proposed as a mechanism by which short regulatory peptides influence gene transcription and epigenetic states, including modulation of DNA methylation patterns associated with cellular aging and differentiation.

In the specific context of cartilage biology, Cartalax has been described in the literature as a chondroprotector, with proposed activity centered on the regulation of chondrocyte proliferation markers, such as Ki-67 expression, and on signaling pathways implicated in chondrogenic differentiation of mesenchymal stem cells, including WNT, ERK-p38 (mitogen-activated protein kinase), and Smad 1/5/8 signaling cascades. These pathways converge on the transcriptional regulation of key chondrogenic genes and structural proteins, including SOX9, type II collagen (COL2), and aggrecan (ACAN), which govern extracellular matrix composition and cartilage tissue integrity. Related short peptides in the bioregulator class have also been described as influencing skin fibroblast function, suggesting a broader connective-tissue regulatory role for this structural family of peptides beyond cartilage alone.

Key Research Findings

Published research on Cartalax and the broader short-peptide bioregulator class provides converging evidence for a role in cartilage and connective tissue regulation, situated within a larger body of work on peptide-mediated gene expression.

Khavinson and colleagues, in a systematic review of peptide regulation of gene expression, described the molecular basis by which short peptides of two to seven amino acid residues interact with nucleosomes, histone proteins, and single- and double-stranded DNA. Within this review, Cartalax is specifically discussed alongside related peptides for its role in the regulation of cartilage and skin fibroblast functions, with the authors proposing that such peptides can complementarily bind short nucleotide sequences in gene promoter regions to modulate transcriptional activity (Khavinson et al., 2021).

Linkova and colleagues reviewed the molecular mechanisms underlying peptide regulation of chondrogenic differentiation of mesenchymal stem cells (MSCs) in the context of osteoarthritis research, cataloguing peptides — including AED — studied for their capacity to regulate WNT, ERK-p38, and Smad signaling pathways during chondrogenic differentiation, and their downstream effects on chondrogenic marker gene expression (Linkova et al., 2023).

Earlier foundational work by Anisimov and Khavinson summarized several decades of research into peptide bioregulation of aging, describing a broad experimental and observational research program examining how tissue-specific short peptide bioregulators, administered in various animal models, correlate with markers of biological aging across multiple organ systems, including connective tissue (Anisimov & Khavinson, 2010).

Complementary review work by Khavinson on peptide regulation of cell differentiation further describes how short peptides can participate in activating signaling pathways that regulate the expression of differentiation-associated genes, including through direct interaction with histone proteins that alter chromatin accessibility (Khavinson, 2020).

Taken together, this literature situates Cartalax within a defined peptide bioregulator research tradition emphasizing epigenetic and transcriptional mechanisms, with cartilage-specific findings concentrated on chondrocyte proliferation markers and chondrogenic differentiation signaling pathways rather than on any single, isolated mechanism of action.

Chemical Properties & Specifications

• Common name: Cartalax
• Chemical designation: Ala-Glu-Asp (AED) tripeptide
• Peptide class: Short peptide bioregulator (bioregulator peptide family)
• Amino acid sequence: Alanine – Glutamic acid – Aspartic acid
• Molecular formula: Approximately C₁₂H₁₉N₃O₈
• Molecular weight: Approximately 333.3 g/mol
• Appearance: White to off-white lyophilized powder
• Storage: Store lyophilized peptide at -20°C, protected from moisture and light. Once reconstituted, solutions should be stored at 2-8°C and used within the timeframe established by the supplying laboratory; repeated freeze-thaw cycling should be avoided to preserve peptide integrity.

Research Applications

Cartalax is used in laboratory research primarily within the fields of cartilage biology, connective tissue physiology, and molecular gerontology. Specific research applications include in vitro chondrocyte culture studies examining proliferation markers such as Ki-67, investigations of chondrogenic differentiation of mesenchymal stem cells and the associated WNT, MAPK, and Smad signaling pathways, and broader studies of the peptide bioregulator class’s proposed epigenetic mechanisms, including DNA- and histone-binding activity relevant to gene transcription.

Researchers in the bioregulator peptide field also study Cartalax as part of comparative work examining tissue-selective activity across the broader family of short regulatory peptides, several of which have been associated in the literature with different organ systems, such as skin, cartilage, and vasculature. Additional research contexts include biogerontology studies exploring the relationship between short peptide bioregulators and markers of cellular and tissue aging, and structural biology research using molecular modeling and docking approaches to characterize how short peptides such as Cartalax interact with DNA and histone targets at the molecular level.

Given the persistent research interest in non-surgical approaches to studying osteoarthritis-related cartilage degeneration, Cartalax and related chondroprotective peptides continue to be examined as tool compounds for probing the molecular signaling that governs chondrocyte health, extracellular matrix maintenance, and the balance between anabolic and catabolic processes in cartilage tissue. Researchers frequently position such short peptide bioregulators alongside other classes of cartilage-directed research molecules, including growth-factor-derived peptides and extracellular matrix-mimetic peptides, when designing comparative in vitro or ex vivo cartilage models. This comparative framing has helped clarify which structural and signaling features are shared across chondroprotective peptide classes and which appear unique to the short bioregulator peptide family that includes Cartalax.

References

1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules.
2. Linkova NS, et al. (2023). Peptide Regulation of Chondrogenic Stem Cell Differentiation. International Journal of Molecular Sciences.
3. Anisimov VN, Khavinson VK. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology.
4. Khavinson VK. (2020). Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports.